We already knew about the changes to the CEO, Senior Management, Board of Directors, and Scientific Advisory Board. But the retention of a number of experienced, strategic consultants is VERY encouraging. From yesterday's MD&A:

• "Bonnie Goldmann, M.D. (Goldmann Consulting, LLC), previously Johnson & Johnson and Merck, is our strategic regulatory advisor who will oversee regulatory strategy.
• Arin Bose, Ph.D. (AbiologicsB, LLC), previously of Pfizer, is serving as our CMC strategic advisor and will support the selection and oversight of the antibody clinical manufacturing.
• Caroline Hill, Ph.D., (previously of Bristol Myers Squibb) has been brought on board to oversee operations and project management.
• Stanley Roberts, Ph.D. (SAR Safety Assessment, LLC), previously of Abbott and CovX/Pfizer, is serving as our preclinical safety and PK strategic advisor and will support and oversee our toxicology program.
• Patrick Yeramian, M.D., Ph.D., previously of Viragen Inc, G.D. Searle Pharmaceuticals and the Vaccine and Gene Therapy Institute of Florida, is our clinical strategic advisor and will oversee the GCP clinical programs."